Illumina deal takes Agendia’s tests directly to hospitals 

Partners to develop new tests for breast cancer as part of push to decentralize NGS testing

January 21, 2022 3:21 AM UTC

A deal with Illumina will enable Agendia to sell its MammaPrint kits directly to hospitals that have the tool company’s equipment, enabling the institutions to run the Dutch company’s breast cancer diagnostic test onsite and be reimbursed $3,800 from CMS.

“Our market research showed that hospitals would prefer to do genomic profiling internally than send it out,” Agendia N.V. CEO Mark Straley told BioCentury, “And there is a large installed base of Illumina platforms.”...

BCIQ Company Profiles

Agendia N.V.

Illumina Inc.